Cognitive Effects of Nimodipine in Patients With Schizophrenia

• Status: Suspended
• Trial end date: 2023-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional MRI scan, with the goal of linking brain activity with working memory performance. Investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the A allele for the Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP) (rs1006737) in comparison to the response of G carriers.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Nimodipine

Criteria

Inclusion Criteria:

• This study will recruit patients with schizophrenia and/or schizoaffective disorder

Exclusion Criteria:

• past or current neurological disorder (including stroke, brain tumor, epilepsy, Alzheimer's, Parkinson's or Huntington's disease)

• uncontrolled medical disorder

• current or past hypotension

• head trauma with loss of consciousness in the last year or any evidence of functional impairment due to and persisting after head trauma

• positive pregnancy test, or currently breast feeding

• having an adverse reaction to nimodipine, or other calcium channel blocker